Novavax : CHMP Recommends Approval Of Its COVID-19 Booster Vaccine

Novavax Inc. (NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, said that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization or CMA in the European Union as a homologous and heterologous booster for active immunization to prevent COVID-19 caused by the SARS-CoV-2 for adults aged 18 and older.

The Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency based its opinion on results from two Phase 2 trials, and the UK-sponsored COV-BOOST trial.

Nuvaxovid has also been approved in Japan, Australia, and New Zealand as a booster in adults aged 18 and older, and is actively under review in other markets.

The European Commission previously granted CMA for Nuvaxovid in adults aged 18 and older in December 2021. In addition, the Commission granted CMA for Nuvaxovid to prevent COVID-19 in adolescents aged 12 through 17 in July 2022.

The trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT